FARNUM RHONDA (SVP, Comm & Medical Affairs) sold 10.1% of their position (31.07K shares) of THERAVANCE BIOPHARMA, INC. on the open market
Open‑market sale worth $582.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 12/5/2025ACC: 0001898490-25-000008
Officer· SVP, Comm & Medical Affairs
Since Dec 2021
-31.07K
Net shares
Net seller
$582.5K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
31.07K disposed
Non-Derivative Transactions3
Ordinary Shares
Direct
Shares
−7.77K
Price / share
$18.75
Trade value
$145.63K
% of position
2.5%
12/3/2025
308.76K→301K
Ordinary Shares
Direct
Shares
−7.77K
Price / share
$18.75
Trade value
$145.62K
% of position
2.6%
12/3/2025
301K→293.23K
Ordinary Shares
Direct
Shares
−15.53K
Price / share
$18.75
Trade value
$291.25K
% of position
5.3%
12/3/2025
293.23K→277.69K
Total
Net shares
−31.07K
Net value
-$582.50K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 12/3/2025 | S · Sale | −7.77K | $18.75 | $145.63K | 2.5% | 308.76K | 301K |
| Ordinary Shares Direct | 12/3/2025 | S · Sale | −7.77K | $18.75 | $145.62K | 2.6% | 301K | 293.23K |
| Ordinary Shares Direct | 12/3/2025 | S · Sale | −15.53K | $18.75 | $291.25K | 5.3% | 293.23K | 277.69K |
| Total | −31.07K | -$582.50K | ||||||
Derivative Transactions0
No derivative transactions reported